PE20141204A1 - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa - Google Patents

Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Info

Publication number
PE20141204A1
PE20141204A1 PE2013002531A PE2013002531A PE20141204A1 PE 20141204 A1 PE20141204 A1 PE 20141204A1 PE 2013002531 A PE2013002531 A PE 2013002531A PE 2013002531 A PE2013002531 A PE 2013002531A PE 20141204 A1 PE20141204 A1 PE 20141204A1
Authority
PE
Peru
Prior art keywords
oxo
diacilglicerol
aciltransferase
inhibitors
novel compounds
Prior art date
Application number
PE2013002531A
Other languages
English (en)
Spanish (es)
Inventor
Donghui Qin
Mui Cheung
Hemant Joshi
Raghuram Tangirala
Sridhar Reddy Bethi
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of PE20141204A1 publication Critical patent/PE20141204A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PE2013002531A 2011-05-20 2012-05-18 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa PE20141204A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1452DE2011 2011-05-20
US201161503728P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
PE20141204A1 true PE20141204A1 (es) 2014-10-05

Family

ID=47217645

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002531A PE20141204A1 (es) 2011-05-20 2012-05-18 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Country Status (34)

Country Link
US (4) US8859536B2 (enExample)
EP (1) EP2710013B1 (enExample)
JP (1) JP5844456B2 (enExample)
KR (1) KR101919080B1 (enExample)
CN (1) CN103703009B (enExample)
AU (1) AU2012259044B2 (enExample)
BR (1) BR112013029935B1 (enExample)
CA (1) CA2836669C (enExample)
CO (1) CO6811855A2 (enExample)
CR (1) CR20130602A (enExample)
CY (1) CY1118188T1 (enExample)
DK (1) DK2710013T3 (enExample)
DO (1) DOP2013000272A (enExample)
EA (1) EA023030B1 (enExample)
ES (1) ES2588748T3 (enExample)
HR (1) HRP20161089T1 (enExample)
HU (1) HUE028870T2 (enExample)
IL (1) IL229488A (enExample)
LT (1) LT2710013T (enExample)
MA (1) MA35185B1 (enExample)
ME (1) ME02479B (enExample)
MX (1) MX346494B (enExample)
MY (1) MY184553A (enExample)
PE (1) PE20141204A1 (enExample)
PH (1) PH12013502401A1 (enExample)
PL (1) PL2710013T3 (enExample)
PT (1) PT2710013T (enExample)
RS (1) RS55006B1 (enExample)
SG (1) SG195044A1 (enExample)
SI (1) SI2710013T1 (enExample)
SM (1) SMT201600328B (enExample)
UA (1) UA111360C2 (enExample)
WO (1) WO2012162129A1 (enExample)
ZA (1) ZA201308664B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
EP3492474B1 (en) 2012-11-23 2021-08-11 GlaxoSmithKline LLC Intermediates used in the production of diacylglycerol acyltransferase inhibitors
WO2014081996A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
WO2015049668A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
WO2015049667A1 (en) 2013-10-03 2015-04-09 Glaxosmithkline Intellectual Property (No.2) Limited Novel compound as a diacylglycerol acyltransferase inhibitor
CN103880757B (zh) * 2014-04-15 2016-02-24 上海毕得医药科技有限公司 一种5-羟基嘧啶-2-羧酸的合成方法
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN105732461A (zh) * 2016-02-03 2016-07-06 常州工程职业技术学院 5-甲氧基-6-卤代吲哚的制备方法
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN107619932B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
CN107619928B (zh) * 2016-07-15 2020-08-07 中国科学院上海有机化学研究所 一种萃取组合物、萃取体系及其应用
RU2706655C1 (ru) * 2019-01-28 2019-11-19 Акционерное общество "Гознак" (АО "Гознак") Полимерсодержащее композиционное защищенное изделие
CN117603242B (zh) * 2023-11-30 2026-08-11 沧州普瑞东方科技有限公司 一种反式-1-乙氧乙烯基-2-硼酸频那醇酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
JP2012520887A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
KR101919080B1 (ko) 2011-05-20 2018-11-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors

Also Published As

Publication number Publication date
CN103703009A (zh) 2014-04-02
AU2012259044B2 (en) 2015-09-17
US20160200736A1 (en) 2016-07-14
US9540400B2 (en) 2017-01-10
AU2012259044A1 (en) 2013-12-12
SG195044A1 (en) 2013-12-30
PT2710013T (pt) 2016-09-28
SI2710013T1 (sl) 2016-10-28
MX2013013566A (es) 2014-01-08
CO6811855A2 (es) 2013-12-16
DOP2013000272A (es) 2014-05-15
KR20140045415A (ko) 2014-04-16
IL229488A (en) 2016-04-21
MA35185B1 (fr) 2014-06-02
UA111360C2 (uk) 2016-04-25
HUE028870T2 (en) 2017-01-30
US8859536B2 (en) 2014-10-14
BR112013029935A2 (pt) 2016-09-20
HRP20161089T1 (hr) 2016-10-21
NZ617991A (en) 2015-06-26
US9040517B2 (en) 2015-05-26
ES2588748T3 (es) 2016-11-04
CA2836669A1 (en) 2012-11-29
CA2836669C (en) 2019-03-19
HK1194738A1 (zh) 2014-10-24
IL229488A0 (en) 2014-01-30
ME02479B (me) 2017-02-20
EP2710013B1 (en) 2016-06-29
US9273069B2 (en) 2016-03-01
JP2014517839A (ja) 2014-07-24
SMT201600328B (it) 2016-11-10
EP2710013A1 (en) 2014-03-26
WO2012162129A1 (en) 2012-11-29
EA201391737A1 (ru) 2014-04-30
RS55006B1 (sr) 2016-11-30
KR101919080B1 (ko) 2018-11-16
LT2710013T (lt) 2016-09-12
PH12013502401A1 (en) 2015-10-07
MX346494B (es) 2017-03-21
JP5844456B2 (ja) 2016-01-20
ZA201308664B (en) 2015-02-25
MY184553A (en) 2021-04-02
BR112013029935B1 (pt) 2020-12-15
CN103703009B (zh) 2016-08-17
DK2710013T3 (en) 2016-09-26
EA023030B1 (ru) 2016-04-29
PL2710013T3 (pl) 2017-08-31
EP2710013A4 (en) 2014-11-05
CY1118188T1 (el) 2017-06-28
US20150225425A1 (en) 2015-08-13
CR20130602A (es) 2014-08-13
US20140080809A1 (en) 2014-03-20
US20140378434A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
PE20141558A1 (es) Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
PE20141726A1 (es) Heterociclilaminas como inhibidores de pi 3k
MA37405A1 (fr) Composés hétérocyclyle
CA2875877C (en) Syk inhibitors
HN2012001037A (es) Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos
PE20150706A1 (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
IN2014MN02106A (enExample)
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
MX348860B (es) Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
MY164790A (en) Purification of bio-based acrylic acid to crude and glacial acrylic acid
PE20141410A1 (es) 3,4 dihidro 1h[1,8] naftiridinonas antibacterianas sustituidas con ciclopenta [c] pirrol
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
PH12014502453A1 (en) Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)- chromen-4-one derivatives and their use in preparing pharmaceuticals
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
PE20141168A1 (es) Derivados de pirazolidin-3-ona

Legal Events

Date Code Title Description
FG Grant, registration